Background: Cardiovascular complications are common in patients with obstructive sleep apnea (OSA). Blood rheology is a major determent of coagulation and an established risk factor for cardiovascular events. Since nocturnal hypoxemia could influence parameters of blood rheology, we hypothesized that OSA alters blood rheology independent of other cardiovascular risk factors. Methods: One hundred and ten consecutive patients admitted to the sleep laboratory were included. The association of plasma fibrinogen and viscosity (as parameters of blood rheology) with OSA was evaluated. Results: One hundred and ten patients aged 61.4 ± 10.1 years (body mass index 28.4 ± 4.1 kg/m2) were included. OSA was confirmed in 63 patients (57.2%) with an apnea-hypopnea index (AHI) of 28.7 ± 14.9 events/hour. Patients with OSA showed higher levels of plasma viscosity (1.36 ± 0.09 vs. 1.31 ± 0.08 mPas, p = 0.005). Nevertheless, hypertensive apneics have even higher levels of plasma viscosity than nonapneics (1.38 ± 0.091 vs. 1.32 ± 0.028 mPas, p = 0.018). Similar results were found in patients with coronary artery disease, where OSA was associated with elevated plasma viscosity (1.36 ± 0.076 vs. 1.31 ± 0.081 mPas, p = 0.007). Plasma fibrinogen was correlated with nocturnal minimal oxygen saturation (r = –0275, p = 0.0036) and AHI (r = 0.297, p = 0.001). OSA was associated with higher plasma fibrinogen (353 ± 83 vs. 317 ± 62 mg/dl, p = 0.015). These differences persist with control for cardiovascular risk factors. Conclusions: Patients with OSA have elevated morning fibrinogen levels and a higher plasma viscosity, which correlate positively with indices of sleep apnea severity. These changes in blood rheology are independent of cardiovascular risk factors, and therefore, might be specific mechanisms of OSA. This supports the pathophysiological concept that sleep apnea is a cardiovascular risk factor.

Keywords:
Sleep apnea, Fibrinogen, Blood rheology, Cardiovascular risk
1.
Partinen M, Guilleminault C: Daytime sleepiness and vascular morbidity at seven-year follow-up in obstructive sleep apnea patients. Chest 1990;97:27–32.
2.
Peker Y, Hedner J, Kraiczi H, Löth S: Respiratory disturbance index. An independent predictor of mortality in coronary artery disease. Am J Respir Crit Care Med 2000;162:81–86.
3.
Guardioloa J, Fletcher E, Alhariri H, Hassan N: Hypercoagulability in obstructive sleep apnea. Clin Pulm Med 2001;8:238–241.
4.
von Clauss A: Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957;17:237–246.
5.
Leschke M, Schoebel F, Mecklenbeck W, Stein D, Jax TW, Müller-Gärtner HW, Strauer BE: Long-term intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris: A randomized dose-response trial. J Am Coll Cardiol 1996;27:575–584.
6.
Koenig W, Ernst E: The possible role of hemorheology in atherothrombogenesis. Atherosclerosis 1992;94:93–107.
7.
Thompson S, Kienast J, Pyke S, Haverkate F, Van de Loo JW: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995;332:635–641.
8.
Montalescot G, Collet J, Choussat R, Thomas D: Fibrinogen as a risk factor for coronary artery disease. Eur Heart J 2001;19:H11–H17.
9.
Strauer BE: Rheologie des Koronarkreislaufes bei Hypertonie; in Strauer BE (ed): Das Hochdruckherz. Berlin, Springer, 1991, pp 207–209.
10.
Wessendorf TE, Thilmann AF, Wang YM, Schreiber A, Konietzko N, Teschler H: Fibrinogen levels and obstructive sleep apnea in ischemic stroke. Am J Respir Crit Care Med 2000;162:2039–2042.
11.
Chin K, Ohi M, Kita H, Noguchi T, Otsuka N, Tsuboi T, Mishima M, Kuno K: Effects of nCPAP therapy on fibrinogen levels in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 1996;153:1972–1976.
12.
Bokinsky G, Miller M, Ault K, Husband P, Mitchell J: Spontaneous platelet activation and aggregation during obstructive sleep apnea and its response to therapy with nasal continuous positive airway pressure. A preliminary investigation. Chest 1995;108:625–630.
13.
Rangemark C, Hedner J, Carlson J, Gleerup G, Winther K: Platelet function and fibrinolytic activity in hypertensive and normotensive sleep apnea patients. Sleep 1995;18:188–194.
14.
von Känel R, Le D, Nelesen R, Mills PJ, Ancoli-Israel S, Dimsdale JE: The hypercoagulable state in sleep apnea is related to comorbid hypertension. J Hypertens 2001;19:1445–1451.
15.
Shamsuzzaman ASM, Winnicki M, Lanfranchi P, Wolk R, Kara T, Accurso V, Somers VK: Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 2002;105:2462–2464.
16.
Ross R: Atherosclerosis – An inflammatory disease. N Engl J Med 1999;340:115–126.
17.
Dyugovskaya L, Lavie P, Lavie L: Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. Am J Respir Crit Care Med 2002;165:934–939.
18.
Ohga E, Nagase T, Tomita T, Teramoto S, Matsuse T, Katayama H, Ouchi Y: Increased levels of circulating ICAM-1, VCAM-1, and L-selectin in obstructive sleep apnea syndrome. J Appl Physiol 1999;87:10–14.
19.
Harley SL, Sturge J, Powell JT: Regulation by fibrinogen and its products of intercellular adhesion molecule-1 expression in human saphenous vein endothelial cells. Arterioscler Thromb Vasc Biol 2000;20:652–658.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.